Charles River Laboratories International (CRL) EBT Margin (2016 - 2025)
Historic EBT Margin for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to 8.68%.
- Charles River Laboratories International's EBT Margin fell 3600.0% to 8.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.55%, marking a year-over-year decrease of 133200.0%. This contributed to the annual value of 2.3% for FY2024, which is 117800.0% down from last year.
- According to the latest figures from Q3 2025, Charles River Laboratories International's EBT Margin is 8.68%, which was down 3600.0% from 6.92% recorded in Q2 2025.
- Charles River Laboratories International's EBT Margin's 5-year high stood at 22.27% during Q4 2022, with a 5-year trough of 21.62% in Q4 2024.
- For the 5-year period, Charles River Laboratories International's EBT Margin averaged around 10.53%, with its median value being 12.13% (2022).
- As far as peak fluctuations go, Charles River Laboratories International's EBT Margin soared by 41900bps in 2022, and later tumbled by -422200bps in 2024.
- Charles River Laboratories International's EBT Margin (Quarter) stood at 18.08% in 2021, then increased by 23bps to 22.27% in 2022, then dropped by -8bps to 20.59% in 2023, then tumbled by -205bps to 21.62% in 2024, then soared by 140bps to 8.68% in 2025.
- Its last three reported values are 8.68% in Q3 2025, 6.92% for Q2 2025, and 3.66% during Q1 2025.